Literature DB >> 6401518

Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children.

J Ludvigsson, L Heding, G Liedén, B Marner, A Lernmark.   

Abstract

Several factors indicate that autoimmune mechanisms may play a part in the aetiology of insulin-dependent diabetes mellitus. At the onset of the disease in 10 children (aged 11-16 years) plasmapheresis was performed four times over one to two weeks. Seventeen age-matched children with the same clinical features served as controls. The C-peptide concentrations at onset were the same in the two groups, but after one month the children treated with plasmapheresis had significantly higher values. This difference became even more pronounced after three, nine, and 18 months, both during fasting and at the maximum response to a standardised meal. The study group also had a significantly more stable metabolism, longer partial remission, and no higher insulin requirement. Of the 10 treated children islet-cell cytoplasmic antibodies were present in seven before plasmapheresis and in nine during treatment. The antibodies remained detectable in five and six out of nine patients at one and six months respectively after plasmapheresis. Although the mechanisms are obscure, plasmapheresis performed at the onset of insulin-dependent diabetes mellitus may help to preserve beta-cell function.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6401518      PMCID: PMC1546360          DOI: 10.1136/bmj.286.6360.176

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  13 in total

1.  Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.

Authors:  P C Dau; J M Lindstrom; C K Cassel; E H Denys; E E Shev; L E Spitler
Journal:  N Engl J Med       Date:  1977-11-24       Impact factor: 91.245

2.  Plasmapheresis and immunosuppressive therapy. Effect on levels of intercellular antibodies in pemphigus vulgaris.

Authors:  R Auerbach; J C Bystryn
Journal:  Arch Dermatol       Date:  1979-06

3.  Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies.

Authors:  G F Bottazzo; A Florin-Christensen; D Doniach
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

4.  Treatment by plasma exchange of a patient with autoantibodies to the insulin receptor.

Authors:  M Muggeo; J S Flier; R A Abrams; L C Harrison; A B Deisserroth; C R Kahn
Journal:  N Engl J Med       Date:  1979-03-01       Impact factor: 91.245

5.  Radioimmunological determination of human C-peptide in serum.

Authors:  L G Heding
Journal:  Diabetologia       Date:  1975-12       Impact factor: 10.122

6.  Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome.

Authors:  C M Lockwood; A J Rees; T A Pearson; D J Evans; D K Peters; C B Wilson
Journal:  Lancet       Date:  1976-04-03       Impact factor: 79.321

7.  beta-cell function in children with diabetes.

Authors:  J Ludvigsson; L G Heding
Journal:  Diabetes       Date:  1978       Impact factor: 9.461

8.  Glycosylated haemoglobin concentrations and clinitest results in insulin-dependent diabetes.

Authors:  R Lanoe; J Soria; N Thibult; C Soria; E Eschwege; G Tchobroutsky
Journal:  Lancet       Date:  1977-12-03       Impact factor: 79.321

Review 9.  Immune and autoimmune aspects of diabetes mellitus.

Authors:  B S Handwerger; G Fernandes; D M Brown
Journal:  Hum Pathol       Date:  1980-07       Impact factor: 3.466

10.  Regulation of antibody formation by serum antibody. II. Removal of specific antibody by means of exchange transfusion.

Authors:  J C Bystryn; M W Graf; J W Uhr
Journal:  J Exp Med       Date:  1970-12-01       Impact factor: 14.307

View more
  29 in total

1.  Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial.

Authors:  J Ludvigsson; U Samuelsson; J Ernerudh; C Johansson; L Stenhammar; G Berlin
Journal:  Arch Dis Child       Date:  2001-08       Impact factor: 3.791

Review 2.  Immune intervention yes, but for what reason, for whom, when and how?

Authors:  A Lernmark
Journal:  Diabetologia       Date:  1992-11       Impact factor: 10.122

Review 3.  Overview of prevention and intervention trials for type 1 diabetes.

Authors:  Jorge Daaboul; Desmond Schatz
Journal:  Rev Endocr Metab Disord       Date:  2003-12       Impact factor: 6.514

4.  Immune intervention in children with type 1 diabetes.

Authors:  Johnny Ludvigsson
Journal:  Curr Diab Rep       Date:  2010-10       Impact factor: 4.810

5.  Epilepsy and behavioral changes, type 1 diabetes mellitus and a high titer of glutamic acid decarboxylase antibodies.

Authors:  Esther Ganelin-Cohen; Dalit Modan-Moses; Rina Hemi; Hannah Kanety; Bruria Ben-Zeev; Christiane S Hampe
Journal:  Pediatr Diabetes       Date:  2015-12-29       Impact factor: 4.866

6.  The use of FK 506 in new-onset type I diabetes in man.

Authors:  P B Carroll; A G Tzakis; C Ricordi; H R Rilo; K Abu-Elmagd; N Murase; Y J Zeng; R Alejandro; D Mintz; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

7.  Antigen presentation of detergent-free glutamate decarboxylase (GAD65) is affected by human serum albumin as carrier protein.

Authors:  Jordan Steed; Lisa K Gilliam; Robert A Harris; Ake Lernmark; Christiane S Hampe
Journal:  J Immunol Methods       Date:  2008-03-07       Impact factor: 2.303

8.  The Fourth International Serum Exchange Workshop to standardize cytoplasmic islet cell antibodies. The Immunology and Diabetes Workshops and Participating Laboratories.

Authors:  A Lernmark; J L Molenaar; W A van Beers; Y Yamaguchi; S Nagataki; J Ludvigsson; N K Maclaren
Journal:  Diabetologia       Date:  1991-07       Impact factor: 10.122

Review 9.  Immunological aspects on IDDM in children.

Authors:  J Ludvigsson
Journal:  Indian J Pediatr       Date:  1989 Nov-Dec       Impact factor: 1.967

Review 10.  The role of immunotherapy in type I diabetes mellitus.

Authors:  M E Geffner; B M Lippe
Journal:  West J Med       Date:  1987-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.